TP-3654 is under clinical development by Sumitomo Dainippon Pharma Oncology and currently in Phase II for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According to GlobalData, Phase II drugs for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how TP-3654’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
TP-3654 (SGI-9481) is under development for the treatment of bladder cancer, primary or secondary myelofibrosis including post-essential thrombocythemia myelofibrosis, triple negative breast cancer, post-polycythemia vera myelofibrosis and hematological malignancies (hematological tumor). It is administered through oral route. It is a second generation pan-PIM kinase inhibitor. The drug candidate was also under development for the treatment of psoriasis, prostate cancer, acute myeloid leukemia (AML), lymphoma, chronic lymphocytic leukemia (CLL), solid tumors and urothelial carcinoma.
Sumitomo Dainippon Pharma Oncology overview
Sumitomo Dainippon Pharma Oncology (Sumitomo Dainippon), formerly Boston Biomedical, a subsidiary of Sumitomo Chemical Co Ltd, is a developer of novel therapeutics to treat cancer. The company offers drug discovery, crystallography, medicinal chemistry, preclinical development, pharmacology, pharmaceutical development, clinical trials, and regulatory affair services. Its drug candidates include BBI608 and BBI503. The company also offers cancer stem cell development programs that include cancer cell stemless, signaling pathways, treatment resistance, recurrence and metastasis; resources and CSC programs. Sumitomo Dainippon is headquartered in Cambridge, Massachusetts, the US.
For a complete picture of TP-3654’s drug-specific PTSR and LoA scores, buy the report here.